IBD goes home: from telemedicine to self-administered advanced therapies

References

• Weekly epidemiological update - 23 February 2021. WHO Rep; 2021. 1–25. [cited 2021 Mar 12]. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update—23-february-2021
   Google Scholar
• Fiorino G, Allocca M, Furfaro F, et al. Inflammatory bowel disease care in the COVID-19 pandemic era: the humanitas, milan, experience. J Crohn’s Colitis. 2020;14(9):1330–1333.
   Google Scholar
• Lees CW, Regueiro M, Mahadevan U. Innovation in inflammatory bowel disease care during the COVID-19 Pandemic: results of a global telemedicine survey by the international organization for the study of inflammatory bowel disease. Gastroenterology. 2020;159(3):805–808.e1.
   PubMed Web of Science ®Google Scholar
• D’Amico F, Netter P, Baumann C, et al. Setting up a virtual calprotectin clinic in inflammatory bowel diseases: literature review and nancy experience. J Clin Med. 2020;9(9):2697.
   Web of Science ®Google Scholar
• Danese S, Sands B, Ng SC, et al. The day after COVID-19 in IBD: how to go back to ‘normal.’ Nat Rev Gastroenterol Hepatol. 2020;17(8):441–443.
   PubMed Web of Science ®Google Scholar
• Bossuyt P, Pouillon L, Bonnaud G, et al. E-health in inflammatory bowel diseases: more challenges than opportunities? Dig Liver Dis. 2017;49(12):1320–1326.
   PubMedGoogle Scholar
• Bavafa H, Hitt LM, Terwiesch C. The impact of e-visits on visit frequencies and patient health: evidence from primary care. Manage Sci. 2018;64(12):5461–5480.
   PubMed Web of Science ®Google Scholar
• Jackson BD, Gray K, Knowles SR, et al. EHealth technologies in inflammatory bowel disease: a systematic review. J Crohn’s Colitis. 2016;10(9):1103–1121.
   Google Scholar
• ISD Scotland. SMR Datasets VC. 2015 [cited 2021 Jan 6]. Available from: https://www.ndc.scot.nhs.uk/Data-Dictionary/SMR-Datasets/SMR00-Outpatient-Attendance/Virtual-Clinic
   Google Scholar
• De Jong MJ, van der Meulen-de Jong AE, Romberg-Camps MJ, et al., Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet. 2017;390(10098):959–968.
   PubMed Web of Science ®Google Scholar
• De Jong MJ, Boonen A, van der Meulen-de Jong AE, et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clin Gastroenterol Hepatol. 2020;18(8):1744–1752.
   PubMed Web of Science ®Google Scholar
• Cross RK, Langenberg P, Regueiro M, et al. A randomized controlled trial of telemedicine for patients with inflammatory bowel disease (TELE-IBD). Am J Gastroenterol. 2019;114(3):472–482.
   PubMed Web of Science ®Google Scholar
• Del Hoyo J, Nos P, Faubel R, et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. J Med Internet Res. 2018;20(11):e11602.
   PubMed Web of Science ®Google Scholar
• Singh S, Brill JV, Proudfoot JA, et al. Project sonar: a community practice-based intensive medical home for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2018;16(1847–1850.e1):1847–1850.e1.
   Google Scholar
• Kosinski L, Brill JV, Sorensen M, et al. 824 project sonar: reduction in cost of care in an attributed Cohort of patients with Crohn’s disease. Gastroenterology. 2016;150(4):S173.
   Web of Science ®Google Scholar
• Heida A, Dijkstra A, Muller Kobold A, et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. J Crohn’s Colitis. 2018;12(4):432–441.
   Google Scholar
• Habashi P, Bouchard S, Nguyen GC. Transforming access to specialist care for inflammatory bowel disease: the PACE telemedicine program. J Can Assoc Gastroenterol. 2019;2(4):186–194.
   PubMedGoogle Scholar
• Lim MH, McMahon A, Radford‐Smith GL. Telehealth in inflammatory bowel disease. Intern Med J. 2020; published on line 25 September 2020. DOI:https://doi.org/10.1111/imj.15068.
   Google Scholar
• Hollander JE, Carr BG. Virtually perfect? Telemedicine for Covid-19. N Engl J Med. 2020;382(18):1679–1681.
   PubMed Web of Science ®Google Scholar
• Magro F, Rahier JF, Abreu C, et al. Inflammatory bowel disease management during the COVID-19 outbreak: the ten do’s and don’ts from the ECCO-COVID Taskforce. J Crohn’s Colitis. 2020;14(Supplement_3):S798–S806.
   Google Scholar
• Kennedy NA, Jones GR, Lamb CA, et al. British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut. 2020;69(6):984–990.
   PubMed Web of Science ®Google Scholar
• Allocca M, Fiorino G, Furfaro F, et al., Maintaining the quality standards of care for inflammatory bowel disease patients during the COVID-19 pandemic. Clin Gastroenterol Hepatol. 2020;18(8):1882–1883.
   PubMed Web of Science ®Google Scholar
• Mastronardi M, Curlo M, Polignano M, et al. Remote monitoring empowerment of patients with IBDs during the SARS-CoV-2 pandemic. Healthcare. 2020;8(4):377.
   Web of Science ®Google Scholar
• Kelso M, Feagins LA. Can smartphones help deliver smarter care for patients with inflammatory bowel disease? Inflamm Bowel Dis. 2018;24(7):1453–1458.
   PubMed Web of Science ®Google Scholar
• Angelucci E, Orlando A, Ardizzone S, et al. Internet use among inflammatory bowel disease patients: an Italian multicenter survey. Eur J Gastroenterol Hepatol. 2009;21(9):1036–1041.
   PubMed Web of Science ®Google Scholar
• Szeto W, van der Bent A, Petty CR, et al. Use of social media for health-related tasks by adolescents with inflammatory bowel disease: a step in the pathway of transition. Inflamm Bowel Dis. 2018;24(6):1114–1122.
   PubMed Web of Science ®Google Scholar
• Gecse KB, Vermeire S. Differential diagnosis of inflammatory bowel disease: limitations and complications. Lancet Gastroenterol Hepatol. 2018;3(9):644–653.
   PubMed Web of Science ®Google Scholar
• Lesnovska KP, Börjeson S, Hjortswang H, et al. What do patients need to know? Living with inflammatory bowel disease. J Clin Nurs. 2014;23(11–12):1718–1725.
   PubMed Web of Science ®Google Scholar
• Landy J, Peake ST, Akbar A, et al. OC-160 Telemedicine systems in IBD management—are patients ready? Gut. 2012;61(Suppl 2):A69.
   PubMed Web of Science ®Google Scholar
• Huang VW, Reich KM, Fedorak RN. Distance management of inflammatory bowel disease: systematic review and meta-analysis. World J Gastroenterol. 2014;20(3):829–842.
   PubMed Web of Science ®Google Scholar
• Con D, De Cruz P. Mobile phone apps for inflammatory bowel disease self-management: a systematic assessment of content and tools. JMIR mHealth uHealth. 2016;4(1):e13.
   PubMed Web of Science ®Google Scholar
• Read AJ, Muza-Moons MM. Patient-focused IBD applications review. Gastroenterology. 2017;152(5):1241–1243.
   Google Scholar
• McLean S, Nurmatov U, Liu JL, et al. Telehealthcare for chronic obstructive pulmonary disease: cochrane Review and meta-analysis. Br J Gen Pract. 2012;62(604):e739–49.
   PubMed Web of Science ®Google Scholar
• Kochar B, Martin CF, Kappelman MD, et al. Evaluation of gastrointestinal patient reported outcomes measurement information system (GI-PROMIS) symptom scales in subjects with inflammatory bowel diseases. Am J Gastroenterol. 2018;113(1):72–79.
   PubMed Web of Science ®Google Scholar
• Ghosh S, Louis E, Beaugerie L, et al., Development of the IBD disk: a visual self-administered tool for assessing disability in inflammatory bowel diseases. Inflamm Bowel Dis. 2017;23(3):333–340.
   PubMed Web of Science ®Google Scholar
• Le Berre C, Flamant M, Bouguen G, et al. VALIDation of the IBD-disk instrument for assessing disability in inflammatory bowel diseases in a french cohort: the VALIDate study. J Crohn’s Colitis. 2020;14(11):1512–1523.
   Google Scholar
• Van Deen WK, van der Meulen-de Jong AE, Parekh NK, et al. Development and validation of an inflammatory bowel diseases monitoring index for use with mobile health technologies. Clin Gastroenterol Hepatol. 2016;14(1742–1750.e7):1742–1750.e7.
   PubMed Web of Science ®Google Scholar
• Ankersen DV, Carlsen K, Marker D, et al. Using eHealth strategies in delivering dietary and other therapies in patients with irritable bowel syndrome and inflammatory bowel disease. J Gastroenterol Hepatol. 2017;32:27–31.
   PubMed Web of Science ®Google Scholar
• Pedersen N, Thielsen P, Martinsen L, et al. EHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis. Inflamm Bowel Dis. 2014;20(12):2276–2285.
   PubMed Web of Science ®Google Scholar
• Pedersen N, Elkjaer M, Duricova D, et al. EHealth: individualisation of infliximab treatment and disease course via a self-managed web-based solution in Crohn’s disease. Aliment Pharmacol Ther. 2012;36(9):840–849.
   PubMed Web of Science ®Google Scholar
• Goodday SM, Atkinson L, Goodwin G, et al. The true colours remote symptom monitoring system: a decade of evolution. J Med Internet Res. 2020;22(1):e15188.
   PubMed Web of Science ®Google Scholar
• TrueColours: real time data collection in patients with ulcerative colitis [Doctoral dissertation]. Walsh A. 2017 [cited 2021 Jan 15]. Available from: https://ora.ox.ac.uk/objects/uuid:a4ab55af-5364-4fa4-86ca-e84b917d7f70/download_file?file_format=pdf&safe_filename=DPhil%2BWALSH%2BTRUECOLOURS%2BFEB%2B2018.pdf&type_of_work=Thesis
   Google Scholar
• Mergel I. The long way from government open data to mobile health apps: overcoming institutional barriers in the US federal government. JMIR mHealth uHealth. 2014;2(4):e58. [ cited 2021 Jun 3]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376139
   PubMed Web of Science ®Google Scholar
• Hall JL, Mcgraw D. For telehealth to succeed, privacy and security risks must be identified and addressed. Health Aff. 2014;33(2):216–221.
   PubMed Web of Science ®Google Scholar
• Yang YT, Silverman RD. Mobile health applications: the patchwork of legal and liability issues suggests strategies to improve oversight. Health Aff. 2014;33(2):222–227.
   PubMed Web of Science ®Google Scholar
• Van Mierlo T, Fournier R, Fedorak R. Don’t forget the doctor: gastroenterologists’ preferences on the development of mhealth tools for inflammatory bowel disease. JMIR mHealth uHealth. 2015;3(1):e5.
   PubMed Web of Science ®Google Scholar
• Haisma SM, Galaurchi A, Almahwzi S, et al. Head-to-head comparison of three stool calprotectin tests for home use. PLoS One. 2019;14(4):e0214751.
   PubMed Web of Science ®Google Scholar
• Heida A, Knol M, Muller Kobold A, et al., Agreement between home-based measurement of stool calprotectin and ELISA results for monitoring inflammatory bowel disease activity. Clin Gastroenterol Hepatol. 2017;15(11):1742–1749.e2.
   PubMed Web of Science ®Google Scholar
• Berends SE, D’Haens GRAM, Schaap T, et al., Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: a clinical validation. Br J Clin Pharmacol. 2019;85(7):1544–1551.
   PubMed Web of Science ®Google Scholar
• Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570-1583.
   Google Scholar
• Maaser C, Sturm A, Vavricka SR, et al. ECCO-ESGAR guideline for diagnostic assessment in IBD Part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohn’s Colitis. 2019;13:144–164.
   Google Scholar
• Furfaro F, Vuitton L, Fiorino G, et al. SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience. Nat Rev Gastroenterol Hepatol. 2020;17(8):507–516.
   PubMed Web of Science ®Google Scholar
• Ricciuto A, Griffiths AM. Clinical value of fecal calprotectin. Crit Rev Clin Lab Sci. 2019;56(5):307–320.
   PubMed Web of Science ®Google Scholar
• D’Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(12):2218–2224.
   PubMed Web of Science ®Google Scholar
• D’Amico F, Bonovas S, Danese S, et al. Review article: faecal calprotectin and histologic remission in ulcerative colitis. Aliment Pharmacol Ther. 2020;51(7):689–698.
   PubMed Web of Science ®Google Scholar
• Lasson A, Stotzer PO, Öhmanb L, et al. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohn’s Colitis. 2015;9:26–32.
   Google Scholar
• Lobatón T, López-García A, Rodríguez-Moranta F, et al. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn’s disease. J Crohn’s Colitis. 2013;7(12):e641–51.
   Google Scholar
• Hejl J, Theede K, Møllgren B, et al. Point of care testing of fecal calprotectin as a substitute for routine laboratory analysis. Pract Lab Med. 2018;10:10–14.
   PubMedGoogle Scholar
• CalproSmart Office. [cited 2021 Jan 10]. Avalaible from: https://www.svarlifescience.com/products/cal220
   Google Scholar
• IBDoc® Calprotectin Home Test Kit Procedure - Calprotectin. [ cited 2021 Jun 21]. Available from: https://www.calprotectin.co.uk/calprotectin-products/calprotectin-products-patient-self-testing/ibdoc-calprotectin-home-test-kit-procedure/[Last
   Google Scholar
• QuantOn Cal. [cited 2021 Jan 10]. Available from: https://www.biohithealthcare.co.uk/Diagnostics/Item/QuantOn-Cal
   Google Scholar
• Vinding KK, Elsberg H, Thorkilgaard T, et al. Fecal calprotectin measured by patients at home using smartphones-a new clinical tool in monitoring patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(2):336–344.
   PubMed Web of Science ®Google Scholar
• Ashorov O, Hamouda D, Dickman R, et al. Clinical accuracy of a new rapid assay for fecal calprotectin measurement. Clin Lab. 2020;66(4/2020):671–675.
   Web of Science ®Google Scholar
• Kneepkens EL, Pouw MF, Wolbink GJ, et al. Dried blood spots from finger prick facilitate therapeutic drug monitoring of adalimumab and anti-adalimumab in patients with inflammatory diseases. Br J Clin Pharmacol. 2017;83(11):2474–2484.
   PubMed Web of Science ®Google Scholar
• Vande Casteele N, Feagan BG, Gils A, et al. Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives. Curr Gastroenterol Rep. 2014;16(4):378.
   PubMedGoogle Scholar
• Papamichael K, Vajravelu RK, Vaughn BP, et al. Proactive infliximab monitoring following reactive testing is associated with better clinical outcomes than reactive testing alone in patients with inflammatory bowel disease. J Crohn’s Colitis. 2018;12(7):804–810.
   Google Scholar
• D’Haens G, Vermeire S, Lambrecht G, et al. Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission in patients with active luminal Crohn’s disease. Gastroenterology. 2018;154(1343–1351.e1):1343–1351.e1.
   PubMed Web of Science ®Google Scholar
• Berends SE, Bloem K, De Vries A, et al. Monitoring of adalimumab concentrations at home in patients with inflammatory bowel disease using dried blood samples. Ther Drug Monit. 2020;42(2):289–294.
   PubMed Web of Science ®Google Scholar
• Martial LC, Aarnoutse RE, Schreuder MF, et al. Cost evaluation of dried blood spot home sampling as compared to conventional sampling for therapeutic drug monitoring in children. PLoS One. 2016;11(12):e0167433.
   PubMed Web of Science ®Google Scholar
• Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22–25 June 2020. European medicines agency; 2020 [cited 2021 Jan 14]. Available from: https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-june-2020
   Google Scholar
• Reinisch W, Jang BI, Borzan V, et al., DOP62 A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a Phase I open-label randomised controlled trial in patients with active Crohn’s disease. J Crohn’s Colitis. 2019;13(Supplement_1):S066–S067.
   Google Scholar
• Sandborn WJ, Baert F, Danese S, et al., Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis. Gastroenterology. 2020;158(3):562–572.e12.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Sandborn W, Baert F, et al. OP23 Efficacy and safety of vedolizumab SC in patients with moderately to severely active Crohn’s disease: results of the VISIBLE 2 study. J Crohn’s Colitis. 2020;14(Supplement_1):S020–021.
   Google Scholar
• Vermeire S, D’heygere F, Nakad A, et al. Preference for a prefilled syringe or an autoinjection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover study. Patient Prefer Adherence. 2018;12:1193–1202.
   PubMed Web of Science ®Google Scholar
• Bohra A, Rizvi QA, Keung CYY, et al. Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: a stepwise, safety and patient-orientated process towards sustainability. World J Gastroenterol. 2020;26(36):5437–5449.
   PubMed Web of Science ®Google Scholar
• Verma AM, Patel A, Subramanian S, et al., From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative. Lancet Gastroenterol Hepatol. 2021;6(2):88–89.
   PubMed Web of Science ®Google Scholar
• Li SX, Thompson KD, Peterson T, et al. Delivering high value inflammatory bowel disease care through telemedicine visits. Inflamm Bowel Dis. 2017;23(10):1678–1681.
   PubMed Web of Science ®Google Scholar
• Elkjaer M, Shuhaibar M, Burisch J, et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided ‘constant-care’ approach. Gut. 2010;59(12):1652–1661.
   PubMed Web of Science ®Google Scholar
• Carlsen K, Jakobsen C, Houen G, et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflamm Bowel Dis. 2017;23(9):357–365.
   PubMed Web of Science ®Google Scholar
• Hunter J, Claridge A, James S, et al. Improving outpatient services: the Southampton IBD virtual clinic. Postgrad Med J. 2012;88(1042):487–491.
   PubMed Web of Science ®Google Scholar
• Ankersen DV, Weimers P, Marker D, et al. Costs of electronic health vs. standard care management of inflammatory bowel disease across three years of follow-up–a Danish register-based study. Scand J Gastroenterol. 2021;56(5):520–529.
   PubMed Web of Science ®Google Scholar
• Mobile medical applications: the regulatory framework in the U.S. And the EU - medical product outsourcing. [ cited 2021 Jun 3]. Available from: https://www.mpo-mag.com/issues/2018-06-01/view_columns/mobile-medical-applications-the-regulatory-framework-in-the-us-and-the-eu
   Google Scholar
• Le Berre C, Sandborn WJ, Aridhi S, et al. Application of Artificial Intelligence to Gastroenterology and Hepatology. Gastroenterology. 2020;158(76–94.e2):76–94.e2.
   PubMed Web of Science ®Google Scholar
• McCombie A, Walmsley R, Barclay M, et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflamm Bowel Dis. 2020;26(7):1098–1109.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Cheifetz AS, Melmed GY, et al. Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17(1655–1668.e3):1655–1668.e3.
   PubMed Web of Science ®Google Scholar
• Anderson KC, Landgren O, Arend RC, et al. Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics. Futur Oncol. 2019;15(28):3267–3281.
   PubMed Web of Science ®Google Scholar
• Solitano V, Vuitton L, Peyrin-Biroulet L, et al. The evolution of biologics administration from intravenous to subcutaneous: treatments for inflammatory bowel disease go home. Gastroenterology. 2021;160(7):2244–2247.
   PubMed Web of Science ®Google Scholar